The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on September 18, 2022 that:

• Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older remain in Schedule III
• Brimonidine or its salts, except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older will remain in Schedule I (as per the Prescription Drug List)

were finalized effective November 10, 2022. Final approval of the interim recommendations was made by NAPRA’s Board of Directors. In this case, NAPRA did not receive any comments during the 30-day review period.